Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, entered a manufacturing partnership with WuXi Advanced Therapies, a global contract testing, development and manufacturing organization (CTDMO).  Interius has developed a process to manufacture INT-2104, an off the shelf lentivector product designed to create autologous chimeric antigen receptor (CAR) T cells directly in vivo in a patient’s body for the tr...